ATHELOAttack Helicopter Organization
References in periodicals archive ?
Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with our partner Becton-Dickinson.
This technology has since been licensed by NeoStem's Athelos subsidiary.
Through NeoStem's preclinical VSEL(TM) (very small embryonic-like stem cell) platform, the Phase 1-ready autoimmune disease product candidates of its Athelos subsidiary, and now through AMR-001, NeoStem seeks to fulfill the promise that an individual's own cells hold the potential to both heal and transform the way medicine is delivered.